Viatris VTRS
NASDAQ VTRS
$16.45 -0.16 (-0.93%)
As of: Sep 9, 2026 · 3:13 PM EDT

Viatris (VTRS) Net Income towards Common Stockholders (2019 - 2026)

Viatris (VTRS) posted Net Income towards Common Stockholders of -$118.8 million for Q2 2026, down 167.35% on a QoQ basis from $176.4 million in Q1 2026, and down 2482.61% year-over-year from $5.0 million in Q2 2025.

Analysis

Viatris (VTRS) Net Income towards Common Stockholders (2019 - 2026) Analysis & Trends

Viatris has reported Net Income towards Common Stockholders for 8 years, with the latest figure at -$118.8 million in Q2 2026.

  • On a quarterly basis, Net Income towards Common Stockholders fell 2482.61% year-over-year to -$118.8 million in Q2 2026; TTM through Jun 2026 was -$410.7 million, a 88.16% increase from a year earlier, with the FY2025 full-year figure at -$3.5 billion, down 454.23% from the prior year.
  • Net Income towards Common Stockholders was -$118.8 million for Q2 2026 at Viatris, down from $176.4 million in the prior quarter.
  • The five-year high for Net Income towards Common Stockholders was $1.0 billion in Q4 2022, with the low at -$3.0 billion in Q1 2025.
  • Average Net Income towards Common Stockholders over 5 years is -$108.8 million, with a median of $104.4 million recorded in 2024.
  • The sharpest annual moves came in 2022 and 2025: Net Income towards Common Stockholders surged 483.32% in 2022, then sank 2770.76% in 2025.
  • Over 5 years, Net Income towards Common Stockholders stood at $1.0 billion in 2022, then tumbled by 175.71% to -$765.6 million in 2023, then soared by 32.54% to -$516.5 million in 2024, then surged by 34.15% to -$340.1 million in 2025, then soared by 65.07% to -$118.8 million in 2026.
  • The last three Net Income towards Common Stockholders figures came in at -$118.8 million (Q2 2026), $176.4 million (Q1 2026), and -$340.1 million (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Teva Pharmaceutical Industries 42.55 Bn 38.89 Bn 2.15 Bn -576.00 Mn
2 Viatris 19.15 Bn 18.26 Bn 1.46 Bn -118.80 Mn
3 Dr Reddys Laboratories 9.87 Bn 9.70 Bn 396.53 Mn 46.85 Mn
4 Amneal Pharmaceuticals 5.45 Bn 5.32 Bn 334.51 Mn 69.61 Mn
5 Bausch Health Companies 2.33 Bn 492.63 Mn 2.10 Bn 260.00 Mn
6 Alvotech 1.51 Bn 1.36 Bn 2.56 Mn -66.70 Mn
7 Ani Pharmaceuticals 1.48 Bn 1.12 Bn 165.89 Mn 24.70 Mn
8 Amphastar Pharmaceuticals 992.90 Mn 702.78 Mn 93.47 Mn 30.35 Mn
9 Fennec Pharmaceuticals 401.76 Mn 360.51 Mn 17.15 Mn 1.97 Mn
10 RedHill Biopharma 178.35 Mn 178.35 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -118.80 Mn
Mar 31, 2026 176.40 Mn
Dec 31, 2025 -340.10 Mn
Sep 30, 2025 -128.20 Mn
Jun 30, 2025 -4.60 Mn
Mar 31, 2025 -3.04 Bn
Dec 31, 2024 -516.50 Mn
Sep 30, 2024 94.80 Mn
Jun 30, 2024 -326.40 Mn
Mar 31, 2024 113.90 Mn
Dec 31, 2023 -765.60 Mn
Sep 30, 2023 331.60 Mn
Jun 30, 2023 264.00 Mn
Mar 31, 2023 224.70 Mn
Dec 31, 2022 1.01 Bn
Sep 30, 2022 354.30 Mn
Jun 30, 2022 313.90 Mn
Mar 31, 2022 399.20 Mn
Dec 31, 2021 -263.80 Mn
Sep 30, 2021 311.50 Mn